التفاصيل البيبلوغرافية
| العنوان: |
1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS) |
| المؤلفون: |
Wiesweg, M., Hense, J., Darwiche, K., Michels, S., Hautzel, H., Kobe, C., Metzenmacher, M., Herold, T., Zaun, G., Laue, K., Drzezga, A., Schildhaus, H-U., Wolf, J., Herrmann, K., Schuler, M.H.H. |
| المصدر: |
In Annals of Oncology September 2022 33 Supplement 7:S1084-S1084 |
| قاعدة البيانات: |
ScienceDirect |
